Skip to Content
Merck
  • Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.

Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2009-05-01)
Sara Eyal, Francisco S Chung, Mark Muzi, Jeanne M Link, David A Mankoff, Amal Kaddoumi, Finbarr O'Sullivan, Mary F Hebert, Jashvant D Unadkat
ABSTRACT

Studies in rodents indicate that the disruption of P-glycoprotein (P-gp) function increases drug distribution into the developing fetus and organs such as the brain. To simultaneously and serially evaluate the effect of P-gp activity and inhibition on the tissue distribution of drugs in a more representative animal model, we tested the feasibility of conducting whole-body PET of the pregnant nonhuman primate (Macaca nemestrina). We used (11)C-verapamil as the prototypic P-gp substrate and cyclosporine A (CsA) as the prototypic inhibitor. Four pregnant macaques (gestational age, 145-159 d; gestational term, 172 d) were imaged after the intravenous administration of (11)C-verapamil (30-72 MBq/kg) before and during intravenous infusion of CsA (12 or 24 mg/kg/h, n = 2 each). The content of verapamil and its metabolites in plasma samples was determined using a rapid solid-phase extraction method. The plasma and tissue time-radioactivity concentration curves of (11)C were integrated over 0-9 min after each verapamil injection. The tissue or arterial plasma area under the time-concentration curve (AUC(tissue)/AUC(plasma)) served as a measure of the tissue distribution of (11)C radioactivity. CsA effect on (11)C radioactivity distribution was interpreted as P-gp inhibition. The change in the fetal liver AUC ratio served as a reporter of placental P-gp inhibition. CsA effect on tissue distribution of (11)C radioactivity (AUC ratios) did not increase with the mean blood concentration of CsA, indicating a near-maximal P-gp inhibition. CsA increased maternal brain and fetal liver distribution of (11)C radioactivity by 276% +/- 88% (P < 0.05) and 122% +/- 75% (P < 0.05), respectively. Changes in other measured tissues were not statistically significant. These data demonstrate for the first time, to our knowledge, the feasibility of simultaneous, serial, noninvasive imaging of P-gp activity and inhibition in multiple maternal organs and the placenta in the nonhuman primate. Our findings, consistent with previous data in rodents, indicate that the activity of P-gp in the placenta and the blood-brain barrier is high and that the inhibition of P-gp facilitates drug distribution across these barriers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Zinc, nanopowder, 40-60 nm avg. part. size, ≥99% trace metals basis
Sigma-Aldrich
Zinc, dust, <10 μm, ≥98%
Sigma-Aldrich
Zinc, pieces, 2-14 mesh, 99.9% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 0.25 mm, 99.999% trace metals basis
Sigma-Aldrich
Zinc, granular, 20-30 mesh, ACS reagent, ≥99.8%
Sigma-Aldrich
Zinc, shot, <12 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, shot, 5 mm, 99.999% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, sticks, diam. 7-10 mm, 99.97% trace metals basis
Sigma-Aldrich
Zinc, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.9%, granular
Sigma-Aldrich
Zinc, foil, thickness 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Zinc, powder, <150 μm, 99.995% trace metals basis
Sigma-Aldrich
Zinc, mossy, ≥99%
Sigma-Aldrich
Zinc, purum, powder
Sigma-Aldrich
Zinc, wire, diam. 1.0 mm, 99.995% trace metals basis
Sigma-Aldrich
Zinc, granular, 30-100 mesh, 99%